Ronald A. Pepin
Corporate Officer/Principal bei CELLDEX THERAPEUTICS, INC.
Vermögen: - $ am 31.03.2024
Profil
Ronald A.
Pepin is currently the Director at Antyra, Inc. and the Chief Business Officer & Senior Vice President at Celldex Therapeutics, Inc. He previously worked as the Executive Director-External Science & Technology at Bristol Myers Squibb Co. from 1990 to 2000, and as the Senior Vice President-Business Development at Medarex, Inc. from 2000 to 2009.
He also held a Vice President position at Shire Pharmaceuticals, Inc. Dr. Pepin received his undergraduate degree from Tufts University and his doctorate from Georgetown University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Ronald A. Pepin
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLDEX THERAPEUTICS, INC. | Corporate Officer/Principal | 08.07.2011 |
Antyra, Inc.
 Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Director/Board Member | - |
Ehemalige bekannte Positionen von Ronald A. Pepin
| Unternehmen | Position | Ende |
|---|---|---|
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Corporate Officer/Principal | 01.01.2009 |
| BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | 01.07.2000 |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | - |
Ausbildung von Ronald A. Pepin
| Tufts University | Undergraduate Degree |
| Georgetown University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| Private Unternehmen | 3 |
|---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Antyra, Inc.
Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Health Technology |
